Functional Service Provider (FSP) Medical Writing

Dedicated, sponsor-aligned medical writers embedded within your organization to provide scalable expertise across the development lifecycle.  

Embedded Medical Writing

When development portfolios expand, organizational structures shift, or internal teams reach capacity; medical writing can quickly become a bottleneck to regulatory progress.

ProPharma's FSP Medical Writing model provides dedicated, sponsor-aligned writers who integrate seamlessly into your organization, delivering continuity, scalability, and deep therapeutic expertise without increasing permanent headcount.

FSP models don't just add capacity, they create meaningful "organizational leverage". By shifting the operational management to the FSP partner, organizations significantly reduce administrative burden and unlock strategic capacity. Internal teams are no longer absorbed by managing the day-to-day execution and can instead focus on high-impact priorities such as advancing scientific strategy, shaping regulatory positions, and driving portfolio-level decisions.

Rather than outsourcing individual documents, this model delivers long-term capability: a stable team that operates within your processes, systems, and governance framework.

For project‑based deliverables, explore our Global Medical Writing & Transparency services.

Why Organizations Turn to FSP Medical Writing

Many sponsors adopt an FSP model during periods of transition, growth, or sustained volume pressure. Common drivers include:

  • Acquisition or in-licensing of new compounds that strain existing resources
  • Organizational restructuring that shifts ownership of programs or therapeutic areas
  • Lack of specialized expertise required for complex or niche document types
  • Headcount or budget constraints that prevent permanent hiring
  • Sudden increases in document volume during key development phases
  • Temporary staffing gaps due to extended leave or internal redeployment
  • Learn more about our broader Functional Service Provider capabilities.

Pharma-New-Blogs-8

A Seamless Extension of Your Internal Team

Dedicated FSP writers function as an extension of your internal medical writing organization. We use your SOPs, templates, quality expectations, systems, and governance structure, participating in established communication and review processes. This embedded approach reduces onboarding time, preserves institutional knowledge, and enables consistent output across programs.

Support Across the Development Continuum

FSP Medical Writing teams can support document development across all stages of the drug development lifecycle:

computer-system-validation

Non-Clinical Development

  • Study reports and summaries
  • Investigator's Brochure (Tox, ADME, CMC, etc.)
  • Pharmacology and toxicology documentation
Submissions

Clinical & Regulatory Development

  • Protocols, protocol amendments, and Informed Consent Forms (ICFs)
  • Clinical study reports (CSRs)
  • IND/NDA/BLA submission documentation
  • Safety narratives and summaries
  • Briefing packages and health authority responses
full-service-clinical-trials

Post-Market Safety & Lifecycle Management

  • Periodic safety reports
  • Benefit-risk assessments
  • Lifecycle maintenance documentation
global-literature-review

Publications & Scientific Communication

  • Manuscripts and abstracts
  • Conference materials and presentations
  • Literature reviews and scientific summaries

Peer-Reviewed Journals & Scientific Support

Publishing in peer-reviewed journals is essential for scientific credibility, regulatory engagement, and clinical adoption. FSP teams provide dedicated support across the publication lifecycle: Manuscripts and abstracts

  • Manuscript development for peer-reviewed journals
  • Abstract preparation and conference submissions
  • Journal selection guidance
  • Literature synthesis and evidence framing
  • Author coordination and review management
  • Response-to-reviewer preparation and revisions
  • Compliance with publication guidelines (e.g., ICMJE, GPP)
  • Alignment with Medical Affairs publication strategies
Hands typing on laptop
Woman pointing her coworkers to something on a laptop

Tailored Support Across Biopharma and MedTech

ProPharma supports biotech, pharmaceutical, and medical device/diagnostics organizations navigating diverse regulatory pathways and evidence requirements. Teams are matched to program complexity, therapeutic area, and modality to ensure relevant expertise and regulatory alignment.

Flexible, Scalable Team Structures

FSP Medical Writing solutions are designed to scale with evolving program needs:
  • Single dedicated writers for focused support
  • Multi-writer teams aligned to large portfolios
  • Therapeutic-area specialists
  • Regional expertise for global development
  • Rapid scale-up or scale-down as priorities shift

When an FSP Model is the Right Choice

This model is particularly effective when organizations require ongoing support across multiple programs, predictable demand over extended timelines, integration with internal teams, or scalability without hiring delays.

Shifting operational responsibilities can help reduce administrative and operational burden, allowing internal teams to reclaim time and focus. The result is a more agile, strategically aligned writing function that supports faster, more confident organizational progress.

AdobeStock_714056211

Build the Team That Moves Your Pipeline Forward

Our FSP Medical Writing solutions provide the stability, expertise, and flexibility needed to sustain development momentum, even as priorities evolve. Contact our team to discuss how an embedded medical writing model can support your organization’s goals.

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Understanding For-Cause Audits: A GMP Case Study

May 11, 2026

Understanding For-Cause Audits: A GMP Case Study

Explore the critical role of for-cause audits in GMP environments, uncovering how minor discrepancies can reveal systemic risks and enhance quality oversight.qua

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strategy

May 5, 2026

IND Readiness Isn't a Checkbox Exercise, It's a Regulatory Risk Management Strat...

Preparing for an IND submission? Discover 12 critical questions sponsors should answer to reduce FDA risk, avoid delays, and strengthen submission readiness.

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow